Literature DB >> 8454033

Intimal hyperplasia enhances myosin phosphorylation in rabbit carotid artery.

M Seto1, K Yano, Y Sasaki, H Azuma.   

Abstract

We examined physiological events in the hyperplastic artery, using a method based on the mechanical responsiveness and myosin light-chain phosphorylation in response to various stimulants. Six weeks after endothelial denudation by ballooning of the right carotid artery, strips of this artery with moderate intimal hyperplasia (intimal area was 30-50% of medial area in 20 of 28 rabbits) were used for experiments. Strips from the left carotid served as the normal control. When the hyperplastic artery was stimulated with 30 microM PGF2 alpha, the maximal tension (232.4 +/- 49.1 mg/mg dry wt, mean +/- SD) was significantly higher (P < 0.05) than that of the control (129.5 +/- 16.4 mg/mg). The maximal extent of myosin light-chain monophosphorylation (45.4 +/- 8.9%) and diphosphorylation (10.9 +/- 5.2%) in the hyperplastic artery was significantly higher (P < 0.05) than that in the control artery (33.0 +/- 4.8 and 4.0 +/- 4.8%, respectively). The monophosphorylation of the myosin light chain in the hyperplastic artery was sustained for up to 20 min, while that in the control artery decreased to the basal level within 20 min. Similar observations were obtained by stimulation with 60 mM K+ or 30 microM norepinephrine. Dose-response curves of the development of tension in the hyperplastic artery to various agonists (K+, PGF2 alpha, norepinephrine) shifted upward the curves for the control artery. These results suggest that qualitative changes in the characteristics of smooth muscle cells may occur in the intimal hyperplastic portion, including a hyperreactive contraction associated with enhanced and sustained phosphorylation of the myosin light chain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454033     DOI: 10.1006/exmp.1993.1001

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  8 in total

1.  Myosin regulatory light chain diphosphorylation slows relaxation of arterial smooth muscle.

Authors:  Cindy Sutherland; Michael P Walsh
Journal:  J Biol Chem       Date:  2012-05-31       Impact factor: 5.157

2.  Integrin-linked kinase is responsible for Ca2+-independent myosin diphosphorylation and contraction of vascular smooth muscle.

Authors:  David P Wilson; Cindy Sutherland; Meredith A Borman; Jing Ti Deng; Justin A Macdonald; Michael P Walsh
Journal:  Biochem J       Date:  2005-12-15       Impact factor: 3.857

3.  The involvement of protein kinase C in myosin phosphorylation and force development in rat tail arterial smooth muscle.

Authors:  L P Weber; M Seto; Y Sasaki; K Swärd; M P Walsh
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

4.  Myosin light chain diphosphorylation is enhanced by growth promotion of cultured smooth muscle cells.

Authors:  M Seto; K Sakurada; K E Kamm; J T Stull; Y Sasaki
Journal:  Pflugers Arch       Date:  1996-05       Impact factor: 3.657

5.  Inhibition of intimal hyperplasia in transgenic mice conditionally expressing the chemokine-binding protein M3.

Authors:  Robert Pyo; Kristian K Jensen; Maria T Wiekowski; Denise Manfra; Antonio Alcami; Mark B Taubman; Sergio A Lira
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

Review 6.  Opportunities to Target Specific Contractile Abnormalities with Smooth Muscle Protein Kinase Inhibitors.

Authors:  Annegret Ulke-Lemée; Justin A MacDonald
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-26

Review 7.  Involvement of myosin regulatory light chain diphosphorylation in sustained vasoconstriction under pathophysiological conditions.

Authors:  Kosuke Takeya; Xuemei Wang; Cindy Sutherland; Iris Kathol; Kathy Loutzenhiser; Rodger D Loutzenhiser; Michael P Walsh
Journal:  J Smooth Muscle Res       Date:  2014

Review 8.  Highly sensitive myosin phosphorylation analysis in the renal afferent arteriole.

Authors:  Kosuke Takeya
Journal:  J Smooth Muscle Res       Date:  2016
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.